Harrow, Inc. Capital Expenditures Incurred but Not yet Paid
Harrow, Inc. (HROW) reported Capital Expenditures Incurred but Not yet Paid of $74.00 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-10.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-03-02
- Harrow, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was -$56.00K, a 142.11% decline year-over-year.
- Harrow, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-06-30 was $125.00K.
- Harrow, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-03-31 was $5.00K, a 94.38% decline year-over-year.
- Harrow, Inc. capital expenditures incurred but not yet paid for the quarter ending 2024-12-31 was -$96.00K, a 133.33% decline year-over-year.
- Harrow, Inc. capital expenditures incurred but not yet paid for fiscal 2024 was $81.00K, a 72.91% decline from fiscal 2023.
- Harrow, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $299.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2025-09-30 | -$56.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $69.00K derived: sum of 2 quarters · filed 2025-11-10 | $74.00K 10-Q · filed 2025-11-10 | -$22.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2025-06-30 | $125.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $130.00K 10-Q · filed 2025-08-11 | $34.00K derived: sum of 3 quarters · filed 2026-03-02 | $167.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2025-03-31 | $5.00K 10-Q · filed 2025-05-08 | -$91.00K derived: sum of 2 quarters · filed 2026-03-02 | $42.00K derived: sum of 3 quarters · filed 2026-03-02 | -$3.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-12-31 | -$96.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $37.00K derived: sum of 2 quarters · filed 2026-03-02 | -$8.00K derived: sum of 3 quarters · filed 2026-03-02 | $81.00K 10-K · filed 2026-03-02 |
| 2024-09-30 | $133.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $88.00K derived: sum of 2 quarters · filed 2025-11-10 | $177.00K 10-Q · filed 2025-11-10 | $465.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | -$45.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $44.00K 10-Q · filed 2025-08-11 | $332.00K derived: sum of 3 quarters · filed 2026-03-02 | $228.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $89.00K 10-Q · filed 2025-05-08 | $377.00K derived: sum of 2 quarters · filed 2026-03-02 | $273.00K derived: sum of 3 quarters · filed 2026-03-02 | |
| 2023-12-31 | $288.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $184.00K derived: sum of 2 quarters · filed 2026-03-02 | $299.00K 10-K · filed 2026-03-02 | |
| 2023-09-30 | -$104.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $11.00K 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $115.00K 10-Q · filed 2024-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |